Samsung Biologics, one of the world's largest contract drug manufacturers, posted record third-quarter revenue on Tuesday, driven by its existing factories running at full capacity. The South Korean company said revenue reached 1.490 trillion won (about $1.1 billion) for the quarter ended September 30, beating the 1.395 trillion won that analysts at FactSet had expected.
But the headline sales beat came with a catch: operating margin narrowed to 43% from 50.4% a year earlier, and net income also declined year over year. That combination is a familiar pattern for companies that are investing heavily in new production capacity.
What is a CDMO and why does utilization matter?
Samsung Biologics is a contract development and manufacturing organization, or CDMO. In plain terms, it makes drugs for other pharmaceutical companies that either don't have their own manufacturing plants or want extra capacity. The company doesn't own the drugs it produces; it charges clients for the service of developing and manufacturing them.
For a CDMO, the rate at which its factories are used—called utilization—is a key driver of revenue. When plants are full, the company can sell as much manufacturing capacity as it has. When plants are empty, those fixed costs still pile up but no revenue comes in to cover them.
The company said its record sales were lifted by "full plant utilization" at plants 1 through 4, while plant 5 is still ramping up. It also pointed to help from its newly acquired site in Maryland, in the United States.
Why margins fell despite record sales
The margin squeeze is typical when new capacity comes online. Building and validating a new plant involves large upfront fixed costs—depreciation, staffing, and regulatory validation—that hit the income statement before enough production volume arrives to spread those costs out.
In other words, the company is paying for the future today. Plant 5 and the Maryland facility are not yet running at full tilt, so their costs are weighing on profitability even as the older plants churn out record revenue.
This is a common story across industries that invest in big-ticket assets. Think of a hotel that opens a new wing: the construction and staffing costs show up immediately, but the extra rooms only start generating revenue as guests book them. Until occupancy rises, the hotel's profit margin looks worse than before.
What investors should watch next
The key question for Samsung Biologics is how quickly the new sites move from ramp-up to steady output. The company has a cumulative order book of more than $21.9 billion, which gives it a long runway of contracted work. But converting that backlog into revenue is only half the battle; the other half is doing it efficiently enough to restore margins.
When a CDMO says its main plants are fully utilized, it signals strong demand—but it also means near-term revenue growth is increasingly limited by capacity. That puts the spotlight on execution: bringing plant 5 and the Maryland facility up to high utilization fast enough that fixed costs stop weighing on margins.
Until that utilization inflection shows up, Samsung Biologics can keep converting its order book into revenue without delivering the same step-up in earnings power. That's why investors may focus more on the margin path than on another quarterly sales beat.
For everyday investors, this is a reminder that a company can beat sales expectations and still see its stock react poorly if profitability disappoints. Revenue growth is only part of the story; how efficiently a company generates that revenue matters just as much.
In the broader market, other companies are facing similar dynamics. For example, Tesla's revenue beat hid rising costs from its AI and robotaxi bets, showing that even high-growth names can see margins squeezed by heavy investment. And Meta's AI ad tools lifted sales past forecasts, but investors there are also watching how much the company spends on AI infrastructure.
For Samsung Biologics, the next few quarters will be telling. If plant 5 and Maryland start contributing meaningfully to revenue, the margin pressure should ease. If not, the company could keep posting record sales while profits lag—a situation that often leaves investors feeling uneasy.
